An interventional study of Baduanjin Exercise and Cognitive Fitness Program in Cognitive Decline, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Cognitive Dysfunction by Massachusetts General Hospital — 14 open to participants now, 16 under way, none of them phase 3. Cognitive Dysfunction · Massachusetts General Hospital.
Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, this one is the 5th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2020, is one of 17 with no phase, and was the 9th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →14 of the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 55+
Massachusetts General Hospital · Sites in United States
Ages 40–99 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 50–80 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 25–50
Massachusetts General Hospital · Sites in United States
Ages 50+
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 124 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 40 across the 27 interventional studies, 226 across the 6 observational. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
10 of the studies in Cognitive Dysfunction by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05857137Massachusetts General HospitalPsychosis TMS Study | 2026-11-30 |
| NCT05881239Massachusetts General HospitalDigital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD | 2026-12-30 |
| NCT06538311Massachusetts General HospitalTranscranial Magnetic Stimulation Treatment for Alzheimer's Disease | 2027-03-31 |
| NCT07236190Massachusetts General HospitalBiomarker-based Trial of NPC-1 for Alzheimer's Pathology | 2027-06 |
| NCT05904132Massachusetts General HospitalIndividual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 33 studies in Cognitive Dysfunction by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate the modulation effects of Baduanjin (BDJ), a simple and innovative mind-body exercise, on cognitive function, resting state functional connectivity, and brain morphometry in individuals with subjective cognitive decline (SCD). The results obtained will provide novel insights for improving the prevention of age-related cognitive decline and Alzheimer's disease.
Subjective cognitive decline (SCD), the self-reported perception of memory or cognitive problems, is receiving increasing attention as a risk factor for the development of Alzheimer's disease (AD). Since SCD manifests before the onset of clinical impairment, it might be the optimal stage/window of time at which to intervene with preventative therapies for AD and age-related dementia before the progressive neurological loss and irreversible cognitive impairment.
Recently, mind-body interventions have demonstrated their potential in preventing cognitive decline. Nevertheless, these mind-body therapies encompass a family of complex practices, each with different characteristics and focus. Therefore, they may be associated with different mechanisms and treatment effects. Baduanjin (BDJ) is an innovative and simple mind-body exercise consisting of eight simple movements that can be easily practiced at home with video guidance, thereby making it a more suitable option for older adults with cognitive decline than other more complex exercises.
We believe that this study will 1) significantly improve the prevention of MCI and AD and directly benefit patients suffering from these highly prevalent disorders, 2) enhance the investigators' understandings of the neurobiology through which mind-body interventions affect cognition and health, and 3) advance the investigators' understandings of the pathophysiology and development of SCD, AD, and age-related dementia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
Other: Baduanjin Exercise
This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
Other: Cognitive Fitness Program
Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
Alzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite
The ADCS-PACC is a composite of well-validated neuropsychological tests selected for their sensitivity to detect the earliest cognitive decline from normal to subtly abnormal performance. In this study, the ADCS-PACC will be reported as a z-transformed composite score, where a z-score of 0 represents the reference population mean and each 1.0 z-score unit corresponds to one standard deviation (SD) from that mean. Higher (more positive) z-scores indicate better cognitive performance, whereas lower (more negative) z-scores indicate worse cognitive performance. We will interpret changes over time as standardized change in global cognition. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention).
Time frame: baseline, 3, 6, 9 months
Functional Connectivity of Hippocampus and DLPFC
Resting-state functional connectivity (rsFC) between the hippocampus and the dorsolateral prefrontal cortex (DLPFC) will be quantified from resting-state functional magnetic resonance imaging (rs-fMRI) data. Specifically, we will compute the correlation between the hippocampal seed time series and the time series from a right DLPFC region of interest (ROI), and report connectivity as a Fisher r-to-z-transformed correlation coefficient (zFC) to support statistical inference. Higher (more positive) zFC values indicate stronger positive coupling, values near 0 indicate little to no coupling, and negative values indicate anticorrelation between regions. In typical rs-fMRI data, Fisher z-transformed connectivity values generally fall within an interpretable range of approximately -0.5 to +0.5. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention) and the prespecified primary endpoint.
Time frame: baseline, 3, 6 months
The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory Domain
The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory domain is an 8-item self-report measure of perceived changes in everyday memory functioning compared with the participant's functioning approximately 10 years earlier. Each item is rated on a 4-point scale ranging from 1 (better or no change) to 4 (consistently much worse). The Everyday Memory domain score is calculated as the average of the completed item scores and ranges from 1 to 4. Higher scores indicate greater perceived decline in everyday memory functioning and represent a worse outcome, while lower scores indicate less perceived decline and represent a better outcome. Here we report the change in this score from baseline to the post-treatment assessment (post-treatment (6 month) - baseline).
Time frame: baseline, 3, 6, 9 months
Patient Reported Outcomes Measurement Information System 29 (PROMIS-29)
PROMIS-29 domain subscore is used to assess Physical Function (includes 4 items). Physical Function score ranges from 4-20 (higher = better function). We report the change in Physical Function from baseline to 6 months as the pre-specified primary time point.
Time frame: baseline, 3, 6, 9 months
Brain Morphometry
We will quantify bilateral hippocampal volume at baseline and Month 6 (end of intervention) and report the change (Month 6 - baseline). Volumes will be reported in mm³ (and, if applicable, normalized to total intracranial volume). Higher volume indicates greater structural integrity; decreases indicate atrophy. Values are non-negative and typically \~2,000-5,000 mm³ per hemisphere in adults (method- and age-dependent). We will report the observed mean change scores (Δmm³).
Time frame: baseline, 3, 6 months
Blood Markers
p-tau217 (Tau 217) is a blood/CSF biomarker closely linked to Alzheimer's pathology, rising early with amyloid and increasing further with tau tangle burden. "Normal range" is assay-specific; amyloid-negative values are often \~0.2 pg/mL, with rule-in/abnormal cutoffs commonly \~0.33 pg/mL (plus a gray zone).
Time frame: baseline, 3, 6, 9 months
Heart Rate Variability
Secondary autonomic endpoints from a 5-min ECG included RMSSD. We report change from baseline to 6 months (6-month minus baseline) because 6 months was the prespecified primary time point (end of the intervention), intended to capture more sustained effects while reducing short-term variability/attrition. RMSSD (ms) is non-negative (0 to unbounded) and is commonly used as an index of parasympathetic/vagal modulation.
Time frame: baseline, 3, 6, 9 months
Beck Anxiety Inventory (BAI)
The Beck Anxiety Inventory (BAI) is a 21-item self-report measure of anxiety symptom severity over the past week. Total scores range from 0 to 63 (higher scores indicate greater anxiety). We evaluated change from baseline to month 6, the end of the intervention.
Time frame: baseline, 3, 6, 9 months
Symbol Digit Modalities Test (SDMT)
The Symbol Digit Modalities Test (SDMT) is a brief, well-validated measure of processing speed, attention, and visual scanning. Performance is typically the number of correct symbol-digit pairings completed within the time limit (commonly 90 seconds), with scores ranging from 0 to 110 (higher is better). We evaluated change from baseline to month 6, the end of the intervention.
Time frame: baseline, 3, 6, 9 months
The Stroop Color and Word Test (SCWT)
The Stroop Color and Word Test (SCWT) is a widely used measure of selective attention, processing speed, and inhibitory control. Specifically, it measures the ability to suppress the automatic tendency to read a word rather than name the ink color. The slowing in performance caused by this conflict is called Stroop interference. The interference score is often calculated as the additional time required to complete the incongruent color-word condition relative to a baseline (neutral or congruent) condition, with lower time indicating better performance. Scores range from approximately 0 seconds (no interference) to an unbounded upper limit constrained by test duration. We report the change in interference score from post-treatment to baseline.
Time frame: baseline, 3, 6, 9 months
Trail Making Test Parts A and B Set-Shifting Cost
The Trail Making Test (TMT) Parts A and B measure processing speed, attention, and executive function. Part A assesses visual scanning and speeded sequencing, while Part B additionally requires set-shifting between numbers and letters. Performance on each part is measured as completion time in seconds, with shorter completion times indicating better performance. The outcome reported is the set-shifting cost, calculated as (TMT Part B completion time - TMT Part A completion time)/(TMT Part B completion time + TMT Part A completion time). This is intended to quantify the additional time required for the executive set-shifting demands of Part B while accounting for individual differences in overall processing speed. Lower values indicate better executive performance, whereas higher values indicate worse executive performance. The measure has no established clinical cutoff or threshold values. We report the change in set-shifting cost from baseline to post-treatment.
Time frame: baseline, 3, 6, 9 months
Controlled Oral Word Association Test, Category Fluency and Category Switching
The Controlled Oral Word Association Test (COWAT), Category Fluency, and Category Switching assess verbal fluency and executive control (letter-based word generation, semantic word generation, and switching between categories). Participants are asked to alternately generate words belonging to two semantic categories during a timed trial. Scores are typically the number of correct, non-repeated words produced within the timed trial(s) (practical range 0 to \>40, with higher scores indicating better performance). There are no established clinical threshold or cutoff values for this measure. We evaluated change from baseline to month 6.
Time frame: baseline, 3, 6, 9 months
Patient Reported Outcomes Measurement Information System - Cognition Function and Ability Subset
The PROMIS® Cognitive Function and Cognitive Function-Abilities item banks assess patient-reported cognitive concerns and perceived cognitive abilities (e.g., memory, attention, mental clarity). Scores are typically reported as T-scores standardized to the U.S. general population (mean 50, SD 10), with higher scores indicating better perceived cognitive function/abilities. We evaluated change from baseline to month 6, the end of the intervention.
Time frame: baseline, 3, 6, 9 months
The California Verbal Learning Test-II (CVLT-II)
The California Verbal Learning Test-II (CVLT-II) is a standardized measure of verbal learning and episodic memory for adolescents and adults. The Short-Delay Free Recall trial assesses the ability to recall a word list approximately 2 minutes after completion of the learning phase. Results are reported as age-adjusted Z-scores based on published normative data. A Z-score of 0 represents the normative population mean, positive Z-scores indicate performance above the population mean (better memory performance), and negative Z-scores indicate performance below the population mean (worse memory performance). There are no universally accepted clinical cutoff values for this outcome. We report the change in Short-Delay Free Recall Z-score from baseline to month 6 (end of the intervention).
Time frame: baseline
Modified Brief Pain Inventory (BPI)
The Brief Pain Inventory (BPI) is a 15-item questionnaire that assesses pain location, intensity, relief, quality, and pain-related interference with daily functioning and quality of life. Here, we report average pain over the past week on a 0-10 numeric rating scale. Lower scores indicate less pain (better outcome) and higher scores indicate more pain (worse outcome). We analyzed change from baseline to month 6, which is the end of the study, and included only participants reporting pain (i.e., BPI average pain ≥ 1).
Time frame: baseline, 3, 6, 9 months
Brief Quantitative Sensory Testing (QST)
Quantitative sensory testing (QST) will be assessed from baseline to month 6, which represents the end of the intervention. QST will include mechanical and heat pain measures, specifically pain threshold and pain tolerance. Expected values can vary by test location/body site (e.g., face vs forearm), as well as participant and contextual factors such as age, sex, skin characteristics, and testing conditions.
Time frame: baseline, 3, 6, 9 months
| Milestone | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Started | 62 | 62 |
| Completed | 47 | 49 |
| Not completed | 15 | 13 |
The ADCS-PACC is a composite of well-validated neuropsychological tests selected for their sensitivity to detect the earliest cognitive decline from normal to subtly abnormal performance. In this study, the ADCS-PACC will be reported as a z-transformed composite score, where a z-score of 0 represents the reference population mean and each 1.0 z-score unit corresponds to one standard deviation (SD) from that mean. Higher (more positive) z-scores indicate better cognitive performance, whereas lower (more negative) z-scores indicate worse cognitive performance. We will interpret changes over time as standardized change in global cognition. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention).
| z score | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Alzheimer Disease Cooperative Study- Preclinical Alzheimer (ADCS-PACC) Cognitive Composite | 0.352323178 ± 0.467849812 | 0.318403324 ± 0.578975626 |
Resting-state functional connectivity (rsFC) between the hippocampus and the dorsolateral prefrontal cortex (DLPFC) will be quantified from resting-state functional magnetic resonance imaging (rs-fMRI) data. Specifically, we will compute the correlation between the hippocampal seed time series and the time series from a right DLPFC region of interest (ROI), and report connectivity as a Fisher r-to-z-transformed correlation coefficient (zFC) to support statistical inference. Higher (more positive) zFC values indicate stronger positive coupling, values near 0 indicate little to no coupling, and negative values indicate anticorrelation between regions. In typical rs-fMRI data, Fisher z-transformed connectivity values generally fall within an interpretable range of approximately -0.5 to +0.5. We reported the change from baseline to 6 months because this is the study's primary timepoint (end of intervention) and the prespecified primary endpoint.
| unitless Fisher z value | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Functional Connectivity of Hippocampus and DLPFC | 0.05 ± 0.1 | -0.05 ± 0.1 |
The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory domain is an 8-item self-report measure of perceived changes in everyday memory functioning compared with the participant's functioning approximately 10 years earlier. Each item is rated on a 4-point scale ranging from 1 (better or no change) to 4 (consistently much worse). The Everyday Memory domain score is calculated as the average of the completed item scores and ranges from 1 to 4. Higher scores indicate greater perceived decline in everyday memory functioning and represent a worse outcome, while lower scores indicate less perceived decline and represent a better outcome. Here we report the change in this score from baseline to the post-treatment assessment (post-treatment (6 month) - baseline).
| units on a scale | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| The Everyday Cognition - Participant Report Form (ECog) - Everyday Memory Domain | -0.022127329 ± 0.584997441 | -0.020043732 ± 0.592822098 |
PROMIS-29 domain subscore is used to assess Physical Function (includes 4 items). Physical Function score ranges from 4-20 (higher = better function). We report the change in Physical Function from baseline to 6 months as the pre-specified primary time point.
| units on a scale | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Patient Reported Outcomes Measurement Information System 29 (PROMIS-29) | -0.153191489 ± 4.879720727 | -0.940816327 ± 4.231672166 |
We will quantify bilateral hippocampal volume at baseline and Month 6 (end of intervention) and report the change (Month 6 - baseline). Volumes will be reported in mm³ (and, if applicable, normalized to total intracranial volume). Higher volume indicates greater structural integrity; decreases indicate atrophy. Values are non-negative and typically \~2,000-5,000 mm³ per hemisphere in adults (method- and age-dependent). We will report the observed mean change scores (Δmm³).
| mmΛ3 | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Brain Morphometry | -43.2 (-106.2 to 19.79) | -27.3 (-89.0 to 34.4) |
p-tau217 (Tau 217) is a blood/CSF biomarker closely linked to Alzheimer's pathology, rising early with amyloid and increasing further with tau tangle burden. "Normal range" is assay-specific; amyloid-negative values are often \~0.2 pg/mL, with rule-in/abnormal cutoffs commonly \~0.33 pg/mL (plus a gray zone).
| pg/ml | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Blood Markers | -0.1 ± 0.3 | -2.4 ± 9.1 |
Secondary autonomic endpoints from a 5-min ECG included RMSSD. We report change from baseline to 6 months (6-month minus baseline) because 6 months was the prespecified primary time point (end of the intervention), intended to capture more sustained effects while reducing short-term variability/attrition. RMSSD (ms) is non-negative (0 to unbounded) and is commonly used as an index of parasympathetic/vagal modulation.
| ms | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Heart Rate Variability | 7.8 ± 27.2 | -3.5 ± 25.8 |
The Beck Anxiety Inventory (BAI) is a 21-item self-report measure of anxiety symptom severity over the past week. Total scores range from 0 to 63 (higher scores indicate greater anxiety). We evaluated change from baseline to month 6, the end of the intervention.
| units on a scale | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Beck Anxiety Inventory (BAI) | -0.425531915 ± 6.439499983 | -0.673469388 ± 5.665641164 |
The Symbol Digit Modalities Test (SDMT) is a brief, well-validated measure of processing speed, attention, and visual scanning. Performance is typically the number of correct symbol-digit pairings completed within the time limit (commonly 90 seconds), with scores ranging from 0 to 110 (higher is better). We evaluated change from baseline to month 6, the end of the intervention.
| score on a scale | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Symbol Digit Modalities Test (SDMT) | 4.608695652 ± 7.596719353 | 3.416666667 ± 7.359559808 |
The Stroop Color and Word Test (SCWT) is a widely used measure of selective attention, processing speed, and inhibitory control. Specifically, it measures the ability to suppress the automatic tendency to read a word rather than name the ink color. The slowing in performance caused by this conflict is called Stroop interference. The interference score is often calculated as the additional time required to complete the incongruent color-word condition relative to a baseline (neutral or congruent) condition, with lower time indicating better performance. Scores range from approximately 0 seconds (no interference) to an unbounded upper limit constrained by test duration. We report the change in interference score from post-treatment to baseline.
| seconds | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| The Stroop Color and Word Test (SCWT) | -3.020212766 ± 8.515443385 | -4.885208333 ± 9.210775371 |
The Trail Making Test (TMT) Parts A and B measure processing speed, attention, and executive function. Part A assesses visual scanning and speeded sequencing, while Part B additionally requires set-shifting between numbers and letters. Performance on each part is measured as completion time in seconds, with shorter completion times indicating better performance. The outcome reported is the set-shifting cost, calculated as (TMT Part B completion time - TMT Part A completion time)/(TMT Part B completion time + TMT Part A completion time). This is intended to quantify the additional time required for the executive set-shifting demands of Part B while accounting for individual differences in overall processing speed. Lower values indicate better executive performance, whereas higher values indicate worse executive performance. The measure has no established clinical cutoff or threshold values. We report the change in set-shifting cost from baseline to post-treatment.
| score on a scale | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Trail Making Test Parts A and B Set-Shifting Cost | 0.018268634 ± 0.14349907 | 0.004165094 ± 0.138221143 |
The Controlled Oral Word Association Test (COWAT), Category Fluency, and Category Switching assess verbal fluency and executive control (letter-based word generation, semantic word generation, and switching between categories). Participants are asked to alternately generate words belonging to two semantic categories during a timed trial. Scores are typically the number of correct, non-repeated words produced within the timed trial(s) (practical range 0 to \>40, with higher scores indicating better performance). There are no established clinical threshold or cutoff values for this measure. We evaluated change from baseline to month 6.
| score on a scale | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Controlled Oral Word Association Test, Category Fluency and Category Switching | 0.434782609 ± 2.30605169 | -0.306122449 ± 3.52493547 |
The PROMIS® Cognitive Function and Cognitive Function-Abilities item banks assess patient-reported cognitive concerns and perceived cognitive abilities (e.g., memory, attention, mental clarity). Scores are typically reported as T-scores standardized to the U.S. general population (mean 50, SD 10), with higher scores indicating better perceived cognitive function/abilities. We evaluated change from baseline to month 6, the end of the intervention.
| T-score | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Patient Reported Outcomes Measurement Information System - Cognition Function and Ability Subset | 1.693478261 ± 5.655494955 | 2.267346939 ± 4.706794192 |
The California Verbal Learning Test-II (CVLT-II) is a standardized measure of verbal learning and episodic memory for adolescents and adults. The Short-Delay Free Recall trial assesses the ability to recall a word list approximately 2 minutes after completion of the learning phase. Results are reported as age-adjusted Z-scores based on published normative data. A Z-score of 0 represents the normative population mean, positive Z-scores indicate performance above the population mean (better memory performance), and negative Z-scores indicate performance below the population mean (worse memory performance). There are no universally accepted clinical cutoff values for this outcome. We report the change in Short-Delay Free Recall Z-score from baseline to month 6 (end of the intervention).
| z score | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| The California Verbal Learning Test-II (CVLT-II) | .86 ± .95 | .83 ± .87 |
The Brief Pain Inventory (BPI) is a 15-item questionnaire that assesses pain location, intensity, relief, quality, and pain-related interference with daily functioning and quality of life. Here, we report average pain over the past week on a 0-10 numeric rating scale. Lower scores indicate less pain (better outcome) and higher scores indicate more pain (worse outcome). We analyzed change from baseline to month 6, which is the end of the study, and included only participants reporting pain (i.e., BPI average pain ≥ 1).
| scores on a scale | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Modified Brief Pain Inventory (BPI) | -0.09 ± 1.44 | -0.26 ± 1.69 |
Quantitative sensory testing (QST) will be assessed from baseline to month 6, which represents the end of the intervention. QST will include mechanical and heat pain measures, specifically pain threshold and pain tolerance. Expected values can vary by test location/body site (e.g., face vs forearm), as well as participant and contextual factors such as age, sex, skin characteristics, and testing conditions.
| kPa | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Brief Quantitative Sensory Testing (QST) | 2.1 ± 5.6 | -5.6 ± 4.2 |
Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baduanjin | 0/62 (0%) | 3/62 (4.8%) | 2/62 (3.2%) |
| Cognitive Fitness Program | 0/62 (0%) | 3/62 (4.8%) | 1/62 (1.6%) |
| Event | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Gall bladder surgeryGastrointestinal disorders | 1/62 | 0/62 |
| Broken shoulderMusculoskeletal and connective tissue disorders | 1/62 | 0/62 |
| COVID hospitalizationRespiratory, thoracic and mediastinal disorders | 0/62 | 1/62 |
| Staph infectionInfections and infestations | 0/62 | 1/62 |
| Heart attackCardiac disorders | 0/62 | 1/62 |
| Skin CancerSkin and subcutaneous tissue disorders | 1/62 | 0/62 |
| Event | Baduanjin | Cognitive Fitness Program |
|---|---|---|
| Scoliosis painMusculoskeletal and connective tissue disorders | 1/62 | 0/62 |
| Viral infectionInfections and infestations | 1/62 | 0/62 |
| depression episodePsychiatric disorders | 0/62 | 1/62 |
individuals with subjective cognitive decline were enrolled in the study.
| Age, Continuous(year) | Baduanjin | Cognitive Fitness Program | Total |
|---|---|---|---|
| Mean | 62.5 ± 12.5 | 63.9 ± 8.0 | 63.7 ± 8.6 |
| Sex: Female, Male(Participants) | Baduanjin | Cognitive Fitness Program | Total |
|---|---|---|---|
| Female | 42 | 35 | 77 |
| Male | 13 | 18 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Baduanjin | Cognitive Fitness Program | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 53 | 50 | 103 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Baduanjin | Cognitive Fitness Program | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 48 | 48 | 96 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(participants) | Baduanjin | Cognitive Fitness Program | Total |
|---|---|---|---|
| United States | 55 | 53 | 108 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Feb 2025, 53 months.
Results were first posted in Nov 2026, 1 year 9 months after primary completion.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 53 months is above that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →